 |
141 Diseases |  |
28 Trials |
|
28 Trials |  |
1532 News |  |
| 1234567891011» |
- | octreotide acetate / Generic mfg.
Journal: Somatostatin analogs for resectable pancreatic neuroendocrine tumors in high-risk surgical patients: Data from a single-center cohort. (Pubmed Central) - Jun 4, 2025
Fifteen patients (75 %) received Lanreotide, and five (25 %) octreotide acetate (Sandostatin
- |||||| Lutathera (lutetium Lu 177 dotatate) / Novartis
Enrollment open, Trial completion date, Trial primary completion date: NETTER-3: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (clinicaltrials.gov) - Jun 4, 2025
P3, N=240, Recruiting, Sponsor: Novartis Pharmaceuticals
Fifteen patients (75 %) received Lanreotide, and five (25 %) octreotide acetate (Sandostatin Not yet recruiting --> Recruiting | Trial completion date: Jul 2032 --> Jan 2034 | Trial primary completion date: Jun 2028 --> Sep 2030
- || Oclaiz (octreotide subcutaneous depot) / Camurus, octreotide acetate / Generic mfg.
PK/PD data, Journal: Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly. (Pubmed Central) - May 26, 2025
P3
This population PK model supports the use of CAM2029 as a potential alternative treatment option to both octreotide IR and long-acting repeatable (LAR) for acromegaly treatment. The octreotide bioavailability for CAM2029 was similar to octreotide IR and approximately 5 to 6
- octreotide acetate / Generic mfg.
Amphicrine tumor of the pancreas- utility of somatostatin receptor directed PET imaging (Science Pavilion) - May 10, 2025 - Abstract #SNMMI2025SNMMI_1045;
The octreotide bioavailability for CAM2029 was similar to octreotide IR and approximately 5 to 6 Surgical pathology demonstrated?a moderately differentiated, grade-2 neuroendocrine tumor with amphicrine differentiation, and a Ki-67 index of 5% (Figure 1).
- Lutathera (lutetium Lu 177 dotatate) / Novartis, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
Optimizing Patient Workflow for Radionuclide Therapy: A Streamlined Approach to Enhance Efficiency and Enable Personalized Dosimetry (Tech Room 1) - May 10, 2025 - Abstract #SNMMI2025SNMMI_657;
This approach ensures compliance, optimizes resources, and prioritizes safety and satisfaction. Future efforts include leveraging machine learning for dosimetry prediction and refining scheduling tools to handle increasing patient volumes.
- ||| Lutathera (lutetium Lu 177 dotatate) / Novartis
Enrollment open: LUMEN-1: 177Lu-DOTATATE for Recurrent Meningioma (clinicaltrials.gov) - May 2, 2025
P2, N=135, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Future efforts include leveraging machine learning for dosimetry prediction and refining scheduling tools to handle increasing patient volumes. Not yet recruiting --> Recruiting
- paltusotine (CRN00808) / Crinetics
Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension (Room 201) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1817;
Not yet recruiting --> Recruiting PATHFNDR-1 was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of switching to paltusotine in patients whose acromegaly was controlled (IGF-I ?1.0
- octreotide acetate / Generic mfg.
Metastatic Insulinoma Refractory to Medical Management (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1356;
After her initial diagnosis, she was started on long acting octreotide 20 mg LAR monthly by her outpatient oncologist and referred to an endocrinologist...With the combination of TPN, IV fluids, and elevated diazoxide and octreotide doses, the patient developed respiratory distress and was intubated. Volume overload is a common side effect of diazoxide and must be closely monitored.
- Oclaiz (octreotide subcutaneous depot) / Camurus
Improved Patient?Reported Outcomes with CAM2029 Treatment, an Octreotide Subcutaneous Depot, in Patients with Acromegaly Previously on Standard-of-Care Injectable Somatostatin Receptor Ligands: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1143;
P3
BackgroundStandard-of-care somatostatin receptor ligand therapies (SoC; octreotide long-acting repeatable/lanreotide Autogel) for acromegaly require in-office administration and can be burdensome. CAM2029, a long-acting, octreotide subcutaneous depot developed using FluidCrystal
- paltusotine (CRN00808) / Crinetics
Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1139;
A simple daily symptom-assessment tool provided important information pertaining to acromegaly disease control that was not apparent from IGF-I measurements. Support: Crinetics Pharmaceuticals
- Oclaiz (octreotide subcutaneous depot) / Camurus
CAM2029, an Octreotide Subcutaneous Depot, Provides Long-Term and Sustained Biochemical Control of Acromegaly: Final Analysis of the Core Part of the ACROINNOVA 2 Phase 3 Trial (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_1137;
P3
Support: Crinetics Pharmaceuticals CAM2029, developed using FluidCrystal
- Octreosphere (octreotide extended release) / Xbrane
Complexities of managing refractory hypoglycemia in a rare case of metastatic grade 2 pancreatic neuroendocrine tumor. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5339;
Ultimately, the case emphasizes the importance of a multidisciplinary approach to optimize outcomes for patients with stage 4 pNETs. Further research is needed to expand the therapeutic arsenal for these rare and aggressive tumors, aiming to improve survival and quality of life for affected individuals.
- Lutathera (lutetium Lu 177 dotatate) / Novartis
Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET): Single institution experience over 15 years. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5080;
This study, conducted at a single institution in Saudi Arabia, reinforces the role of PRRT in improving survival outcomes for NET patients, both as a first-line option after SSA therapy and in later lines of treatment. Results align with international data, supporting its broad applicability
- Cardiac Remodelling and Function in a pituitary-specific Aip-knockout Acromegalic Mouse Model: Impact of First- and Second-Generation Somatostatin Analogues. (Room C2) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_3664;
- Discordant Disease Activity Indicators in a Patient with Acromegaly (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_3027;
- Aggressive Somatotropinoma: Collaborative Management by Endocrinologists and Oncologists (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_3009;
- TSH-Secreting Pituitary Macroadenoma: A Case Report and Therapeutic Considerations (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_3003;
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
A REAL-WORLD STUDY OF LANREOTIDE AUTOGEL FOR THE TREATMENT OF PATIENTS WITH ACROMEGALY IN CHINA: BASELINE INTERIM ANALYSIS (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_2877;
- TREATMENT-RESISTANT GH-SECRETING PITUITARY ADENOMA IN YOUNG PATIENT HARBORING A VARIANT SOMATIC MUTATION OF THE GNAS GENE: A CASE REPORT (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_2871;
- metformin / Generic mfg.
Metformin administration improves treatment response in non-diabetic patients with acromegaly (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_2815;
- Oclaiz (octreotide subcutaneous depot) / Camurus
CAM2029, a self-administered subcutaneous octreotide depot, improved PROs and symptoms in patients with acromegaly in the ACROINNOVA 2 Phase 3 trial: final analysis of the core phase results (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_2814;
- The rare co-occurence of Pituitary Gigantism and Thrombocytopenia ! (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_2354;
- Calcium as a Tumour Marker in PTHrP-Secreting Pancreatic Neuroendocrine Tumour: A Case of Multimodal Management. (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_2127;
- Piqray (alpelisib) / Novartis
Alpelisib therapy for patients with congenital hyperinsulinism (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_1608;
- Thyroid Hormone Resistance Syndrome de Novo in a Patient with THR Mutation c.749T>C. A Case Report. (Hall C of the Bella Centre; ePoster) - Apr 10, 2025 - Abstract #ESPEESE2025ESPE_ESE_1248;
- Lutathera (lutetium Lu 177 dotatate) / Novartis
Quality-of-Life Outcomes of Radioligand Therapy Used in Combination with Systemic Therapies for Neuroendocrine Tumors: A Systematic Review () - Mar 24, 2025 - Abstract #ISPOR2025ISPOR_1476;
Currently, 177 Lu-DOTATATE combined with long-acting octreotide is the only FDA-approved radioligand therapy (RLT) in NETs...Treatments included combinations of RLT with radiosensitizing chemotherapy (n=6, using capecitabine +/- temozolomide), RLT with somatostatin analogues (n=3), and dual RLTs (n=2)... Limited studies reported HRQoL outcomes of RLT combination therapies in NETs, suggesting the need for additional HRQoL evidence to better understand patient experience in these novel treatment regimens.
- | Lutathera (lutetium Lu 177 dotatate) / Novartis, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
New P3 trial: RIALTO: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (clinicaltrials.gov) - Mar 17, 2025
P3, N=166, Not yet recruiting, Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- octreotide acetate / Generic mfg.
A RETROSPECTIVE COHORT STUDY OF LONG-ACTING OCTREOTIDE IN PEDIATRIC PATIENTS WITH PORTAL HYPERTENSION TO PREVENT VARICEAL BLEEDING (Halls C-E, Lower Level - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_4392;
The median age at first dose was 3.19 years [range 0.29-20.58], with a median treatment duration of 0.37 years[range 0-4.17]. Diagnoses included biliary atresia (43%), portal vein thrombosis (27%), and autoimmune hepatitis (7%).
- Octreosphere (octreotide extended release) / Xbrane
Carcinoid Heart Disease With Left Sided Hepatic Hydrothorax and Trapped Lung (Area C, Hall F (North Building, Exhibition Level), Moscone Center; Poster Board # P317) - Feb 24, 2025 - Abstract #ATS2025ATS_1023;
Here we discuss a unique case of carcinoid heart disease presenting with unilateral left-sided hepatic hydrothorax with trapped lung physiology.A 21-year-old male diagnosed with metastatic neuroendocrine tumor, carcinoid syndrome and extensive DVTs on octreotide LAR therapy presented to the ER with dyspnea on exertion and abdominal pain...Surgery involving Tricuspid valve replacement is a common management option for cases refractory to octreotide maintenance therapy and is indicated for severe valvular dysfunction with symptomatic right ventricular failure. While this case provides a unique presentation of CHD with refractory left sided hepatic hydrothorax with a trapped lung, it reiterates the significant of recognizing CHD and promptly referring for replacement of the affected valve.
- |||| Actinium-225 DOTATATE (RYZ101) / BMS
Trial primary completion date: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Jan 28, 2025
P3, N=288, Recruiting, Sponsor: RayzeBio, Inc.
While this case provides a unique presentation of CHD with refractory left sided hepatic hydrothorax with a trapped lung, it reiterates the significant of recognizing CHD and promptly referring for replacement of the affected valve. Trial primary completion date: Jul 2025 --> Dec 2025
- |||||||||| Lutathera (lutetium Lu 177 dotatate) / Novartis
New P3 trial: NETTER-3: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (clinicaltrials.gov) - Jan 22, 2025
P3, N=240, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | capecitabine / Generic mfg.
Trial termination: Lu-Ca-S: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jan 13, 2025
P2, N=35, Terminated, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Trial primary completion date: Jul 2025 --> Dec 2025 Active, not recruiting --> Terminated; Following the publication in the Official Journal of the reclassification of the drug LUTATHERA in band H, it was decided to close the enrolment early on 30/Aug/19.
- | octreotide acetate / Generic mfg.
New trial: Polydeoxyribonucleotide for Elbow Lateral Epicondylitis (clinicaltrials.gov) - Jan 3, 2025
P=N/A, N=48, Completed, Sponsor: Chuncheon Sacred Heart Hospital
- ||| octreotide 3-month extended release (Debio 4126) / Debiopharm
Trial termination: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Dec 26, 2024
P1, N=20, Terminated, Sponsor: Debiopharm International SA
Active, not recruiting --> Terminated; Following the publication in the Official Journal of the reclassification of the drug LUTATHERA in band H, it was decided to close the enrolment early on 30/Aug/19. Active, not recruiting --> Terminated; The recruitment was halted for strategic reasons
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Trial primary completion date: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Dec 18, 2024
P1, N=14, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Terminated; The recruitment was halted for strategic reasons Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- |||| Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion date, Trial primary completion date: SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) - Dec 13, 2024
P3, N=332, Active, not recruiting, Sponsor: Camurus AB
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025
- || octreotide 3-month extended release (Debio 4126) / Debiopharm
Enrollment change: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Dec 2, 2024
P1, N=20, Active, not recruiting, Sponsor: Debiopharm International SA
Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025 N=30 --> 20
- | Lutathera (lutetium Lu 177 dotatate) / Novartis
Journal: Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China. (Pubmed Central) - Nov 28, 2024
P3
https://clinicaltrials.gov/study/NCT05459844?cond=NCT05459844&rank=1 . Registered 5 July 2022.
- Sulanda (surufatinib) / Hutchmed
Preliminary clinical activity of surufatinib combined with octreotide LAR in patients with G1/2 gastroenteropancreatic neuroendocrine tumor (GEP-NET) () - Nov 15, 2024 - Abstract #NANETS2024NANETS_164;
- | octreotide acetate / Generic mfg.
Journal: Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience. (Pubmed Central) - Nov 6, 2024
Registered 5 July 2022. No abstract available
- | octreotide acetate / Generic mfg.
Journal, Metastases: Liver metastasized pancreatic neuroendocrine tumor in a 17-year-old female: A case report. (Pubmed Central) - Nov 6, 2024
The rarity of these tumors makes their diagnosis difficult, but they should not be omitted and must be considered when there are long-lasting symptoms that are not compatible with common illnesses. These tumors are curable in their early stages.
- octreotide acetate / Generic mfg.
Long-Acting Somatostatin Analogues Treatment Patterns and Outcomes in Neuroendocrine Tumor Patients: An Italian Propensity Score Matched Cohort Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1291;
In subsequent treatments, most patients receive SSA with additional therapies. First-line long-acting octreotide and lanreotide showed comparable PFS and OS.
- | octreotide acetate / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Surgery: OTIS: Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer (clinicaltrials.gov) - Oct 31, 2024
P2, N=20, Completed, Sponsor: Fredrik Klevebro
First-line long-acting octreotide and lanreotide showed comparable PFS and OS. Recruiting --> Completed | N=152 --> 20 | Trial completion date: Dec 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
- | Signifor (pasireotide) / Recordati
Journal: Prophylactic somatostatin analogs for postoperative pancreatic fistulas: a cross-sectional survey of AHPBA surgeons. (Pubmed Central) - Oct 2, 2024
These results highlight key areas for future study including understanding surgeon rationale for patient and drug selection. Variable practice patterns amongst surgeons also underscore the importance of generalizability in the design of future clinical trials in order to maximize impact.
- octreotide acetate / Generic mfg.
68Ga-DOTATATE uptake in leiomyoma (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2682;
Although 68Ga-DOTATATE PET/CT scans are highly accurate for neuroendocrine tumors imaging, DOTATATE uptake could also be seen in various non-neuroendocrine conditions, including thymoma, prostatitis, and vertebral haemangioma. And in case of DOTATATE uptake in uterus, diagnosis of leiomyoma should also be considered.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. (Pubmed Central) - Sep 24, 2024
Our long-term experience with octreotide and lanreotide in NET did not reveal differences in antitumor effectiveness. This is consistent with previous reports and might suggest that both SSA can be used interchangeably if needed.
- Clinicopathological profile and outcomes of neuroendocrine tumors: Data from a multicenter collaborative registry in India (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_593;
Conclusions In one of the largest series of NETs from India, we note that GEP-NETs are the commonest, and grade remains the most important prognostic factor. Very few patients have access to PRRT, and most of them receive only chemotherapy agents.
- || Review, Journal: Medical treatment of acromegaly - When the tumor size matters: A narrative review. (Pubmed Central) - Sep 15, 2024
Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).
- |||||| Actinium-225 DOTATATE (RYZ101) / BMS
Enrollment open: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Aug 26, 2024
P3, N=288, Recruiting, Sponsor: RayzeBio, Inc.
In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB). Active, not recruiting --> Recruiting
- | octreotide acetate / Generic mfg.
Journal, Metastases: Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors. (Pubmed Central) - Aug 26, 2024
The OS is significantly lower in patients with associated extrahepatic involvement. These parameters may justify a more aggressive treatment approach in metastatic grade 1 GEP-NETs.